Who are Alemtuzumab infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alemtuzumab (GZ402673), MabCampath-1h, FluCAM [Fludara + Campath].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alemtuzumab-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Alemtuzumab infusion — Competitive Intelligence Brief

Alemtuzumab infusion (Alemtuzumab infusion) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody (CD52-directed). Area: Immunology / Oncology.

marketed monoclonal antibody (CD52-directed) CD52 Immunology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Alemtuzumab infusion (Alemtuzumab infusion) — Johns Hopkins University. Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion of T and B cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Alemtuzumab infusion TARGET	Alemtuzumab infusion	Johns Hopkins University	marketed	monoclonal antibody (CD52-directed)	CD52
Alemtuzumab (GZ402673)	Alemtuzumab (GZ402673)	Genzyme, a Sanofi Company	marketed	Monoclonal antibody (CD52 antagonist)	CD52
MabCampath-1h	MabCampath-1h	University of British Columbia	phase 3	Monoclonal antibody (CD52 antagonist)	CD52
FluCAM [Fludara + Campath]	FluCAM [Fludara + Campath]	Genzyme, a Sanofi Company	phase 3	Combination chemotherapy and monoclonal antibody	Ribonucleotide reductase / DNA polymerase (fludarabine); CD52 (alemtuzumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody (CD52-directed) class)

Johns Hopkins University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alemtuzumab infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/alemtuzumab-infusion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab